Advertisement
LMAT vs SYK
Which Stock Would AI Choose? LeMaitre Vascular (LMAT) vs. Stryker (SYK) Stock Comparison
Key Takeaways
- LMAT is a niche, high-margin vascular-device maker with strong organic growth but recent pressure from foreign-exchange, export, and supply constraints.
- SYK is a diversified, large-cap medical-technology leader recovering from a cyber disruption, with broader revenue scale but a heavier valuation reset.
- LMAT reported roughly 10% organic sales growth and 23% earnings-per-share (EPS) growth in its latest quarter, while SYK rebounded to about 9% organic growth.
- The two companies operate at vastly different scales, offering contrasting risk profiles around concentration versus diversification.
- Relative performance recently favored neither stock sharply, with both trading well below earlier 2026 highs as sentiment recalibrated.
Introduction
This stock comparison examines LeMaitre Vascular and Stryker, two medical-technology companies occupying very different segments of the healthcare market. LMAT focuses narrowly on devices and biologic tissues for peripheral vascular and cardiac surgery, while SYK spans orthopaedics, surgical technologies, and neurotechnology. The pairing is useful for traders and investors weighing a concentrated, high-margin growth story against a diversified industry leader navigating operational recovery. By comparing business models, recent momentum, and market positioning, this article highlights the trade-offs each name presents in the current environment rather than recommending one over the other.
LMAT Overview and Recent Performance
LeMaitre Vascular develops, manufactures, and sells disposable and implantable devices for vascular and cardiac surgery, serving vascular surgeons across the Americas, Europe, and Asia-Pacific. Its latest quarterly results showed roughly 10% organic sales growth, with record operating income and a gross margin around 72%. The company's Artegraft product line was a standout, growing by double digits and accounting for about one-fifth of total sales.
Recent market activity has been more mixed. The shares pulled back notably over the past several weeks as investors weighed a modest sales shortfall tied to a stronger U.S. dollar, Middle East-related export delays, and cardiac allograft (donated heart tissue) supply constraints. A leadership transition, with the company's president planning to retire at year-end, added another variable to the narrative. Despite the pullback, LMAT maintains a strong balance sheet with a substantial cash and securities position, and its dividend and share-repurchase programs remain in place.
SYK Overview and Recent Performance
Stryker is a global medical-technology company operating across MedSurg and Neurotechnology, plus Orthopaedics, with products that include surgical robotics, implants, hospital beds, and emergency-care equipment. Its scale is considerably larger than LMAT, serving more than 150 million patients annually. In its latest quarter, SYK delivered revenue growth near 9.4% and adjusted EPS growth near 18%, supported by strong capital-equipment deliveries and recovering production.
The recent period has been defined by recovery from a cybersecurity disruption that constrained manufacturing and shipments earlier in the year. Sales growth slowed sharply in that disrupted quarter before rebounding, and management narrowed rather than raised full-year guidance. SYK's shares also declined over recent months, with valuation compressing well below its longer-term averages. Positive catalysts include record robotic-system installations and new product launches, while vascular supply back orders and integration demands remain execution risks.
Trending AI Robots
Tickeron operates a large ecosystem of AI-powered trading bots covering thousands of tickers, each with its own trading style, strategy, timeframe, performance statistics, and portfolio of securities. Rather than presenting every available bot, Tickeron curates only the most suitable performers for current market conditions into its Trending AI Robots section. This curated list highlights bots whose recent track records, consistency, and market alignment distinguish them, offering traders a filtered view of quantitative strategies across momentum, trend-following, and mean-reversion approaches. For investors seeking a data-driven, systematic perspective on names like LMAT and SYK, exploring the page can provide additional signal beyond fundamental analysis.
Head-to-Head Comparison
The clearest contrast is scale and diversification. LMAT operates a concentrated portfolio aimed at a specific surgical specialty, which supports exceptional gross margins but leaves it more exposed to single-product and supply-chain shocks. SYK's breadth across multiple franchises reduces dependence on any one line, yet its complexity introduces integration and operational risks that a focused niche player does not face.
Growth profiles also differ. LMAT's expansion is driven by pricing power, geographic rollout of Artegraft, and targeted mergers and acquisitions (M&A, or corporate deal-making), while SYK leans on procedural volume, robotics adoption, and a deep product pipeline. On valuation, LMAT trades at a premium price-to-earnings (P/E) ratio relative to the broader medical-equipment group, whereas SYK's forward multiple has fallen below its own five-year median. Risk factors differ as well: LMAT faces currency, export, and tissue-supply exposure, while SYK faces cyber-remediation costs, vascular back orders, and acquisition execution. In recent months, sentiment cooled on both, though for distinct reasons.
Tickeron AI Verdict
Based on observable factors, Tickeron's AI would likely view SYK's broader trend consistency and improving operational momentum as comparatively more favorable, while recognizing that LMAT's higher margins and niche pricing power offer a differentiated, if more concentrated, profile. A systematic model would weigh SYK's diversified revenue base, recovering sales trajectory, and below-trend valuation against LMAT's smaller scale and supply-driven uncertainty. Probabilistically, the AI would lean toward SYK for relative stability and catalyst breadth, while noting that LMAT could remain attractive for traders focused on higher-margin, specialty exposure once its near-term headwinds show clearer signs of resolution.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is LMAT is a StrongBuy and SYK is a Buy.
LMAT's Stochastic Oscillator is staying in oversold zone for 2 days
Be on the lookout for a price bounce soon.
Technical Analysis (Indicators)
Bullish Trend Analysis
The 10-day moving average for LMAT crossed bullishly above the 50-day moving average on October 15, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 13 of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 76%.
Following a +2.31% 3-day Advance, the price is estimated to grow further. Considering data from situations where LMAT advanced for three days, in 229 of 339 cases, the price rose further within the following month. The odds of a continued upward trend are 68%.
The Aroon Indicator entered an Uptrend today. In 167 of 235 cases where LMAT Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 71%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on LMAT as a result. In 58 of 104 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 56%.
The Moving Average Convergence Divergence Histogram (MACD) for LMAT turned negative on November 06, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 50 similar instances when the indicator turned negative. In 29 of the 50 cases the stock turned lower in the days that followed. This puts the odds of success at 58%.
LMAT moved below its 50-day moving average on November 06, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where LMAT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 53%.
LMAT broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 52 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 55 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.
The Tickeron Price Growth Rating for this company is 69 (best 1 - 100 worst), indicating slightly worse than average price growth. LMAT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 72 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.401) is normal, around the industry mean (4.964). P/E Ratio (28.087) is within average values for comparable stocks, (40.591). Projected Growth (PEG Ratio) (2.178) is also within normal values, averaging (4.143). Dividend Yield (0.012) settles around the average of (0.005) among similar stocks. P/S Ratio (7.267) is also within normal values, averaging (56.876).
The Tickeron PE Growth Rating for this company is 79 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Momentum Indicator for SYK turns positive, indicating new upward trend
SYK saw its Momentum Indicator move above the 0 level on November 02, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 90 similar instances where the indicator turned positive. In 55 of the 90 cases, the stock moved higher in the following days. The odds of a move higher are at 61%.
Technical Analysis (Indicators)
Bullish Trend Analysis
SYK moved above its 50-day moving average on November 02, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for SYK crossed bullishly above the 50-day moving average on October 26, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 10 of 20 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 50%.
Following a +10.70% 3-day Advance, the price is estimated to grow further. Considering data from situations where SYK advanced for three days, in 174 of 305 cases, the price rose further within the following month. The odds of a continued upward trend are 57%.
The Aroon Indicator entered an Uptrend today. In 128 of 258 cases where SYK Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 50%.
Bearish Trend Analysis
The 10-day RSI Indicator for SYK moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 39 similar instances where the indicator moved out of overbought territory. In 21 of the 39 cases, the stock moved lower in the following days. This puts the odds of a move lower at 54%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 33 of 59 cases where SYK's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 56%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SYK declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 50%.
SYK broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 46 (best 1 - 100 worst), indicating steady price growth. SYK’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 52 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 66 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.
The Tickeron Valuation Rating of 79 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.211) is normal, around the industry mean (4.142). P/E Ratio (33.491) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (1.289) is also within normal values, averaging (11.253). Dividend Yield (0.011) settles around the average of (0.011) among similar stocks. P/S Ratio (4.259) is also within normal values, averaging (40.124).
The Tickeron PE Growth Rating for this company is 79 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
LMAT | SYK | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 77 | 77 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 72 Overvalued | 79 Overvalued | |
PROFIT vs RISK RATING 1..100 | 55 | 66 | |
SMR RATING 1..100 | 52 | 52 | |
PRICE GROWTH RATING 1..100 | 69 | 46 | |
P/E GROWTH RATING 1..100 | 79 | 79 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
LMAT's Valuation (72) in the Medical Specialties industry is in the same range as SYK (79). This means that LMAT’s stock grew similarly to SYK’s over the last 12 months.
LMAT's Profit vs Risk Rating (55) in the Medical Specialties industry is in the same range as SYK (66). This means that LMAT’s stock grew similarly to SYK’s over the last 12 months.
LMAT's SMR Rating (52) in the Medical Specialties industry is in the same range as SYK (52). This means that LMAT’s stock grew similarly to SYK’s over the last 12 months.
SYK's Price Growth Rating (46) in the Medical Specialties industry is in the same range as LMAT (69). This means that SYK’s stock grew similarly to LMAT’s over the last 12 months.
SYK's P/E Growth Rating (79) in the Medical Specialties industry is in the same range as LMAT (79). This means that SYK’s stock grew similarly to LMAT’s over the last 12 months.
| LMAT | SYK | |
|---|---|---|
| RSI ODDS (%) | N/A | 1 day ago 54% |
| Stochastic ODDS (%) | 1 day ago 78% | 1 day ago 56% |
| Momentum ODDS (%) | 1 day ago 56% | 1 day ago 61% |
| MACD ODDS (%) | 1 day ago 58% | N/A |
| TrendWeek ODDS (%) | 1 day ago 56% | 1 day ago 51% |
| TrendMonth ODDS (%) | 1 day ago 53% | 1 day ago 50% |
| Advances ODDS (%) | 21 days ago 68% | 8 days ago 57% |
| Declines ODDS (%) | 6 days ago 53% | 1 day ago 50% |
| BollingerBands ODDS (%) | 1 day ago 61% | 1 day ago 68% |
| Aroon ODDS (%) | 1 day ago 71% | 1 day ago 50% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
LMAT’s FA Score shows that 0 FA rating(s) are green while SYK’s FA Score has 0 green FA rating(s).
- LMAT’s FA Score: 0 green, 5 red.
- SYK’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
LMAT’s TA Score shows that 4 TA indicator(s) are bullish while SYK’s TA Score has 5 bullish TA indicator(s).
- LMAT’s TA Score: 4 bullish, 5 bearish.
- SYK’s TA Score: 5 bullish, 4 bearish.
Price Growth
LMAT (@Pharmaceuticals: Other) experienced а -1.96% price change this week, while SYK (@Medical/Nursing Services) price change was +4.42% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +1.96%. For the same industry, the average monthly price growth was +6.35%, and the average quarterly price growth was +22.73%.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -2.89%. For the same industry, the average monthly price growth was -4.69%, and the average quarterly price growth was -1.76%.
Reported Earning Dates
LMAT is expected to report earnings on Feb 25, 2027.
SYK is expected to report earnings on Feb 02, 2027.
Industries' Descriptions
@Pharmaceuticals: Other (+1.96% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
@Medical/Nursing Services (-2.89% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
Advertisement
LMAT and
Correlation & Price change
A.I.dvisor indicates that over the last year, LMAT has been loosely correlated with ITGR. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if LMAT jumps, then ITGR could also see price increases.
| Ticker / NAME | Correlation To LMAT | 1D Price Change % | ||
|---|---|---|---|---|
| LMAT | 100% | +0.34% | ||
| ITGR - LMAT | 48% Loosely correlated | +0.05% | ||
| SYK - LMAT | 46% Loosely correlated | -1.70% | ||
| UFPT - LMAT | 44% Loosely correlated | +0.00% | ||
| AORT - LMAT | 40% Loosely correlated | -1.81% | ||
| RDNT - LMAT | 39% Loosely correlated | +0.18% | ||
More | ||||
SYK and
Correlation & Price change
A.I.dvisor indicates that over the last year, SYK has been loosely correlated with ISRG. These tickers have moved in lockstep 65% of the time. This A.I.-generated data suggests there is some statistical probability that if SYK jumps, then ISRG could also see price increases.